[{"orgOrder":0,"company":"Mirai Bio","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Mirai Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirai Bio \/ Mirai Bio","highestDevelopmentStatusID":"3","companyTruncated":"Mirai Bio \/ Mirai Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Mirai Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Through the collaboration, Thermo Fisher will be paired with Mirai's innovative technology platform for optimizing the design, delivery and development of novel nucleic acid therapeutics.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          May 20, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Recipient : Thermo Fisher Scientific

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank